×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
4SC AG Faces EMA Setback on Resminostat Approval
TipRanks
4SC AG Faces EMA Setback on Resminostat Approval · 4SC AG is a biotech firm focusing on cancer and autoimmune disease drugs. · EMA's objections...
4 months ago
4SC updates on Kinselby marketing application
The Pharma Letter
German clinical-stage biotech 4SC AG today announced that it has submitted its responses to the Day-120 List of Questions from the European Medicines Agency...
6 months ago
4SC Announces an Update to Resminostat's (Kinselby) Marketing Authorisation Application
TradingView
4SC AGby Jason LoveridgePublic disclosure of inside information according to article 17 MAR4SC AG: 4SC Announces an Update to Resminostat's...
4 months ago
PTA-Adhoc: 4SC AG: EMA signals a Negative CHMP Opinion on the Marketing Authorization Application for Resminostat (Kinselby)
TradingView
As a result, 4SC is now discontinuing the further development and commercialization of Resminostat (Kinselby). In the immediate future the...
1 month ago
Albaugh Specialty Products launches Ethofumesate 4SC Select
Golf Course Industry
Featuring a high concentration of active ingredient with low-use rates, Ethofumesate 4SC Select is especially effective for control of Poa annua...
22 months ago
Albaugh Introduces Maxtron 4SC Herbicide to U.S. Crop Protection Market
CropLife
Preemergent applications of Maxtron 4SC protect sugar beets through germination, emergence, and early seedling growth, and have demonstrated effective control...
20 months ago
4SC Provide Q2 2023 and H1 2023 Update
European Pharmaceutical Manufacturer
Highlights in Q2 2023 · The European Medicines Agency (EMA) has notified 4SC that it has accepted its Letter of Intent to Submit a Marketing...
23 months ago
4SC files maintenance CTCL therapy Kinselby in EU
pharmaphorum
4SC files maintenance CTCL therapy Kinselby in EU ... German biotech 4SC has filed its oral HDAC inhibitor Kinselby with the EMA, hoping to...
16 months ago
The oral KIF11 inhibitor 4SC-205 exhibits antitumor activity and potentiates standard and targeted therapies in primary and metastatic neuroblastoma models
Wiley Online Library
The oral KIF11 inhibitor 4SC-205 exhibits antitumor activity and potentiates standard and targeted therapies in primary and metastatic neuroblastoma models.
45 months ago
Theoretical and experimental investigation of diffusion permeability of hybrid MF-4SC membranes with silica nanoparticles
ScienceDirect.com
The diffusion permeability through hybrid materials based on a Nafion-type membrane and hydrated silica is investigated using the Nernst–Planck approach.
91 months ago